MedTrace Logo

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

NCT04250636 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-06-26

Study results available
· View outcomes & findings →

Summary

The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at 30 mg/kg in viremic human immunodeficiency virus (HIV)-infected individuals.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

3BNC117-LS

Intravenous infusion of 3BNC117-LS at 30mg/kg

DRUG

10-1074-LS

Intravenous infusion of 10-1074-LS at 30mg/kg

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Marina Caskey · The Rockefeller University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2022-01-21
Completion
2022-02-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04250636 on ClinicalTrials.gov